Select region
Submit

Subscribe to our news feed

Subscribe

A question?

10/30/2023
Getinge Announces U.S. Commercial Availability of iCast Covered Stent System for Treatment of Iliac Arterial Occlusive Disease

Today Getinge announced commercial availability of the iCast covered stent system in the United States for the treatment of iliac arterial occlusive disease.

10/30/2023
Getinge Announces U.S. Commercial Availability of iCast Covered Stent System for Treatment of Iliac Arterial Occlusive Disease

Today Getinge announced commercial availability of the iCast covered stent system in the United States for the treatment of iliac arterial occlusive disease. In March 2023, the iCast covered stent received premarket approval from the U.S. Food and Drug Administration (FDA) for the treatment of iliac arterial occlusive disease. Lower extremity peripheral artery disease (PAD) is estimated to affect approximately 8.5 million people in the U.S. per year [[[1]]][,[[2]]].

10/23/2023
Getinge Interim Report July - September 2023: Higher sales, gradually strengthened margins and stable cash flows

“Getinge’s sales rose organically by 5.7% in the quarter,” says Mattias Perjos, President & CEO at Getinge. “Most of the operations in Acute Care Therapies performed positively. Sales in Life Science were unchanged and Surgical Workflows grew in all product categories and regions. The order intake declined organically by a total of 1.9% in the quarter, which was exclusively linked to Acute Care Therapies.”

10/11/2023
Getinge acquires Healthmark Industries Co. Inc.

Getinge announced today that it has acquired 100 percent of the shares in US-based Healthmark Industries Co. Inc., a leading provider of innovative instrument care and infection control consumables, for approximately USD 320 M. This strategic step enhances Getinge’s presence within sterile reprocessing in the US and facilitates a global expansion for Healthmark.

10/6/2023
Getinge’s net-zero targets approved by the SBTi

The SBTi’s Target Validation Team today announces that Getinge’s near and long-term targets are aligned with the SBTi's 1.5°C mitigation pathways for reaching net-zero by 2050 or sooner. By this, Getinge commits to reach net-zero greenhouse gas emissions across the value chain by 2050 from a 2021 base year. 

10/3/2023
Getinge invites fund managers, analysts, and media to Q3 Report 2023 conference call

Getinge will issue its Q3 Report 2023 on October 23, 2023, at 08:00 a.m. CEST, followed by a conference call at 10:00-11:00 a.m. CEST, hosted by Mattias Perjos, President & CEO, and Lars Sandström, CFO.

Press Contacts

Jeanette Hedén Carlsson

EVP Communication & Academy
Phone: +46 10 335 1003

Anna Appelqvist

Vice President Corporate Communications
Phone: +46 10 335 5906

Newsroom2

Prefer to contact us online

Click below to fill in the appropriate form. We will be in touch shortly.

Are you looking for

Getinge Hybrid OR

Image Gallery

Diverse picture format made available for press article purpose 

Man and woman looking a something together

About us

All you need to know about Getinge a one glance

Cardiosave

Urgent Medical Device Correction

Voluntary Urgent Medical Device Field Correction for the CARDIOSAVE intra-aortic balloon pump (IABP)

Newsroom

Don't miss anything

Click on the icons and follow us!